“Adding talazoparib to enzalutamide reduced the risk of radiographic progression or death by 52% compared with enzalutamide alone in men with homologous recombination repair (HRR) gene–altered metastatic castration-sensitive prostate cancer (mCSPC), according to findings from the phase 3 TALAPRO-3 trial presented at the 2026 ASCO Annual Meeting.

The primary end point of investigator-assessed radiographic PFS (rPFS) was met with a highly significant and clinically meaningful result.”

From Targeted Oncology.